Also known as: Eli Lilly, Lilly, Lilly Oncology
Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876, it sells products in about 125 countries and is publicly traded on the NYSE as LLY. Its major products include tirzepatide (Mounjaro and Zepbound) and other therapies in diabetes, oncology, and immunology.
Wegovy and Mounjaro prices in South Korea are higher than in China and Japan. South Korea added both drugs to a non-insurance reporting system, but immediate price cuts are unlikely.
Lilly said a Phase IIIb trial of ixekizumab plus tirzepatide in psoriasis and obesity or overweight beat ixekizumab alone on complete skin clearance plus at least 10% weight loss at 36 weeks.
Eli Lilly reported positive phase 3b Together-PsO results for Taltz plus Zepbound in adults with plaque psoriasis and obesity or overweight. Separate meeting updates highlighted new oral plaque psoriasis therapies with biologic-like efficacy.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Insulin list prices rose more than 300% over two decades as PBMs face growing scrutiny over rebates, spread pricing, and transparency. Reform efforts and pharmacist involvement are central to drug affordability and access.
Artios added six senior leaders in 2026 as alnodesertib moved toward late-stage development and potential U.S. commercialization. The company is also running a Phase 2 study of ART6043.
Vermont insurers and employers are scaling back GLP-1 coverage as costs rise, leaving some patients without access. The drugs remain in high demand as studies point to benefits beyond weight loss.
Eli Lilly has launched two Phase 2 trials for brenipatide (LY3537031): RENEW-Op-1 for opioid use disorder and RENEW-Scz-1 for schizophrenia. Both are randomized, double-blind, placebo-controlled studies that are not yet recruiting as of February 2026.
A Johns Hopkins study found GLP-1 users face increased dementia risk after a decade, possibly due to longer lifespan. A separate JCI review found GLP-1 drugs show neuroprotective signals in preclinical studies but consistent cognitive benefits in humans remain unproven.
Isomorphic Labs said one AI-designed drug, ISM8969, has FDA clearance for human clinical trials. The company’s initial pipeline focuses on oncology candidates.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07602582 |
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). |
NOT_YET_RECRUITING | PHASE3 |
| NCT07598370 |
A Study of LY3439539 in Participants With Alzheimer's Disease |
NOT_YET_RECRUITING | PHASE1 |
| NCT07592572 |
A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants |
NOT_YET_RECRUITING | PHASE1 |
| NCT07589608 |
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight |
NOT_YET_RECRUITING | PHASE2 |
| NCT07589595 |
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07572773 |
CHAMP Lung Cancer Screening Program |
NOT_YET_RECRUITING | NA |
| NCT07571200 |
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07571174 |
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07571161 |
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease |
NOT_YET_RECRUITING | PHASE3 |
| NCT07566338 |
A Study of LY4302814 in Healthy Participants |
NOT_YET_RECRUITING | PHASE1 |
